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However, an increasing body of evidence has emerged supporting a role for B cells in regulating immune
responses that extends beyond the production of antibodies. Regulatory B cells play an important role
in immunosuppression, mediated by secretion of anti-inflammatory cytokines. SUMMARY: Successful
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 CURRENTOPINION B-cell responses in allergen immunotherapy
Pattraporn Satitsuksanoaa,b, Willem van de Veena,b, and M€ubeccel Akdisa,b
Purpose of review
The establishment of long-term clinical tolerance in AIT requires the involvement of basophils, mast cells,
allergen-specific regulatory T and B cells, downregulation of effector type 2 responses, and increase in
production of specific IgG, particularly immunglobulin G4 (IgG4) antibodies. This review aims to provide
an overview of the role of B cells in AIT, their mechanism of action, and their potential for improving AIT.
Recent findings
In-depth research of B cells has paved the way for improved diagnosis and research on allergic diseases.
B cells play a central role in allergy and allergen tolerance through the production of immunglobulin E
(IgE)-blocking antibodies. However, an increasing body of evidence has emerged supporting a role for B
cells in regulating immune responses that extends beyond the production of antibodies. Regulatory B cells
play an important role in immunosuppression, mediated by secretion of anti-inflammatory cytokines.
Summary
Successful AIT establishes the reinstatement of immune tolerance toward allergens, reduces allergic
symptoms, and improves clinical treatments in patients. B cells play a central role in this process through
antibody-independent immune regulatory processes in addition to the production of IgE-blocking antibodies.
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INTRODUCTION
Allergic diseases remain a major global health prob-
lem causing significant morbidity and mortality
and accounting for a considerable portion of health-
care expenditures [1]. Allergic diseases develop from
many heterogeneous diseases with different clinical
manifestations. These diseases generally result from
an uncontrolled inflammatory response to allergens
and can lead to a number of disorders, including
food allergy, asthma, allergic rhinoconjunctivitis,
atopic dermatitis, and anaphylaxis [2]. Food allergy
is affecting up to 8% of children and 5% of adults in
westernized countries and, development of thera-
pies for this potentially life-threatening condition
has become a public health priority [3]. Allergic
rhinoconjunctivitis is an allergic disorder of the
nose and eyes affecting about a fifth of the general
population [4]. The prevalence of atopic dermatitis
in longitudinal birth cohort studies is similar in
childhood and adolescence/early adulthood [5].
Anaphylaxis occurs with an incidence of 1.5–7.9
per 100000people/year [6].
There are different endotypes in allergic disor-
ders, which are defined by the compilation of dis-
ease mechanisms explaining disease expression in
groups of patients. Themost common endotypes for
allergic diseases are type 2 and nontype 2; however,
recent data have emerged in support of inflamma-
some subtype, barrier subtype, type 17 subtype, and
mixed types such as type 2/type 1 and type 2/type 17
as well as allergen-specific immunotherapy (AIT)-
responsive endotype [1].
For example, the endotypes in food allergy con-
sists of immunglobulin E (IgE)-mediated immediate
hypersensitivity reactions, non-IgE-mediated reac-
tions, and disorders with mixed IgE-mediated and
cell-mediated immune reactions [7
&&
]. IgE-mediated
allergies are typically immediate onset with reac-
tions ranging frommild to severe to life-threatening
anaphylactic reactions involving single or multiple
organs. Non-IgE and mixed endotypes could be
shown in food protein-induced enterocolitis syn-
drome (FPIES) and eosinophilic esophagitis (EoE).
FPIES, diagnosed in infants and toddlers (with
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spontaneous resolution within 1–5 years), includes
reactions with vomiting and diarrhea primarily
because of food allergy to cow’s milk or soy’s milk
[8]. Patients with EoE have increased levels of thy-
mic stromal lymphopoietin, whereas patients with
EoE-like disease can be distinguished from EoE by
eotaxin-3, Mucin 4, and cadherin-like protein 26
expression levels [9]. Recently, it was shown that
desmoglein-1, an intracellular adhesionmolecule, is
downregulated by IL-13 leading to impaired barrier
function. Tracking of desmoglein-1 in individuals
with EoE can aid in diagnosis and management,
leading to improved precisionmedicine [10]. Recent
studies have shown that children with EoE have
high or very high titers of immunglobulin G4
(IgG4) and low but detectable IgE [11].
One of the most successful treatments that are
available for allergic patients is AIT [12–14]. AIT is an
immune tolerance-inducing treatment that reduces
symptoms of allergic rhinitis and asthma as well as
venom allergy and food allergy [15
&&
,16–18]. It
involves the administration of increasing doses of
the causative allergen and induces the establishment
of long-term clinical tolerance against allergens
[19–21]. Routes of AIT consist of subcutaneous
immunotherapy (SCIT) and sublingual immunother-
apy (SLIT). SCIT is used as a reference therapy andhas
transformed allergic treatments; it improves symp-
toms (asthmaand rhinitis) aswell as thequalityof life
of patients [22,23]. SLIT is now a valid noninvasive
alternative to SCIT, as awell-tolerated and efficacious
treatment for respiratory allergies [24–27].
The molecular and cellular mechanisms of aller-
gen tolerance in humans have been intensively stud-
ied during the past decades, leading to the
identification of crucial processes in the induction
andmaintenanceofallergentolerance.These include
induction of allergen-specific regulatory subsets of
T and B cells, secretion of immune suppressive
secreted factors such as IL-10 and transforming
growth factor-b (TGF-b), production of allergen-spe-
cific IgG4 blocking antibodies, and a decrease in
allergic inflammatory responses by mast cells, baso-
phils, and eosinophils in inflamed tissues [28,29]. It
has been known that regulatory T cells play a central
role in the induction and maintenance of allergen
tolerance [30]; however, data supporting a role for B
cells in these processeshave been increasing in recent




Common allergens originate from naturally occur-
ring proteins of plant and animal-origin [31]. The
allergens are initially broken down by hydrolytic
enzymes in the gastrointestinal tract during the
digestive process. It is hypothesized that allergens
can be modified into different forms and different
structures, which can be processed by antigen-pre-
senting cells, presented on the major histocompati-
bility complex class II molecules and subsequently
recognized by antigen-specific T cells. The naı̈ve
antigen-specific T helper cells differentiate into
effector T-helper 2 (Th2) cells in the presence of
IL-4. A set of interleukins such as IL-4, IL-5, IL-10,
and IL-13 are produced by Th2 cells and induce B
cells to differentiate into IgE-producing plasma cells.
Antigen-specific IgE antibodies directly bind to
high-affinity receptor FceRI on mast cells and baso-
phils. Upon reexposure to the allergen, these spe-
cific IgE antibodies induce degranulation of mast
cells and release of mediators including cytokines,




Immunological tolerance is an active process of
immune responses to specific antigens [32]. The
development of allergen tolerance is often associ-
ated with an increase in allergen-specific regulatory
T (Treg), regulatory B (Breg) cells, allergen-specific
IgG4 antibody production, and decreased activation
of effector cells, such as basophils, mast cells, and
eosinophils. Treg and Breg cells are considered as the
major instrumental cells that have immunosuppres-
sive effects [33,34]. The effects of IL-10 on mono-
cytes and macrophages include inhibition of the
production and release of mediators and antigen-
presentation and the enhancement of phagocytosis
[35]. IL-10 directly acts on CD4þ T cells and down-
regulates IL-2 and interferon gamma-g production
by Th1 cells and of IL-4 and IL-5 production by Th2
cells [36]. The induction of type 2 immune response
that consists of Th2 cells and type 2 innate
KEY POINTS
 AIT induces clinical immune tolerance by reducing
symptoms of allergic patients and has been used as a
possible curative treatment for allergies for more than
a century.
 Breg cells play an important role in induction and
maintenance of immune tolerance during AIT through IL-
10-mediated suppression of effector T cells, inhibition of
dendritic cell maturation, induction of Treg cells and
production of antiinflammatory IgG4 antibodies.
 Recently introduced knowledge on the role of B cells in
AIT are beneficial for vaccine development and may
lead to improved AIT strategies for the treatment of
allergic patients.
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lymphoid cells (ILC2) together with the production
of allergen-specific IgE antibodies and increased
eosinophil numbers in the affected tissues and
peripheral blood is a cause of allergic diseases
[37–39]. The overview of the mechanism of AIT is
explained in Fig. 1. These allergic symptoms have
often reduced the quality of human life on a daily
basis [40,41].
For several decades, the underlying mechanism
of AIT has been intensively studied to understand
the complexity of allergen-specific immune responses
at both molecular and cellular levels [42,43]. In brief,
molecular and cellular events that occur during AIT
can be separated into 4 stages. Within a few hours of
allergen exposure, there is a decrease in mast cell
and basophil activity and degranulation. This stage
is called earlydesensitization. Then,within a fewdays,
allergen-specific Treg and Breg cells are generated,
which leads to the suppression of allergen-specific
effector T-cell subsets are generated. After a few weeks
to months, the allergen-specific antibodies IgE-to-
IgG4 ratio decreases substantially. Finally, decreases
in tissue mast cells, eosinophils, and release of their
mediators are observed after several months after AIT
[28]. Interestingly, allergen-specific Treg and Breg
cells and their microenvironmental cytokines are
important for determining success or failure in
immunotherapy AIT [30,44].
FIGURE 1. The development of allergen tolerance in AIT. AIT, Allergen-specific immunotherapy; Breg, regulatory B cells; ILC2,
group 2 innate lymphoid cells; ILC3, group 3 innate lymphoid cells; TGF-b, transforming growth factor-b; Th2, T-helper 2 cells;
Tr1, allergen-specific regulatory T cells; Treg, regulatory T cells.
Immunotherapy and new treatments
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THE INDUCTION AND DEVELOPMENT OF
REGULATORY B CELLS
Komlósi et al. [45
&
] demonstrated that activated
CD40 ligand (CD40L)-expressing type 3 innate lym-
phoid cells (ILC3s) play an important role in Breg
cell induction in human tonsils. These human cir-
culating ILC3s were able to differentiate into the
activated form of ILC3s (CD40Lþ ILC3s) in the
presence of IL-15. Tonsillar epithelial cells and Mye-
loid Dendritic cells contribute to the supporting
microenvironment of CD40Lþ ILC3s in the tissue
through their IL-15 production. Naive B cells upre-
gulated IL-15 expression on interaction with ILC3s,
and CD40Lþ ILC3-induced IL-15 production was
mediated by B cell activating factor (BAFF) in a BAFF
receptor-dependent manner. Then, CD40Lþ ILC3s
induce the development of IL-10–secreting, pro-
grammed death-ligand 1-expressing functional
Breg cells.
In addition, IL-10 cytokine that plays essential
roles as an effector or regulatory molecules in both
innate and adaptive immune responses is secreted
not only in B cells [34]. The generation of IL-10 and
TGF-b-producing allergen-specific regulatory T cells
(Tr1) have a potential to inhibit Th2-type responses
and suppress other effector T cells through multiple
mechanisms engaging cytotoxic T-lymphocyte-
associated protein 4, programmed death-1 and his-
tamine receptor 2 [46]. During AIT, IL-10 is primar-
ily produced by allergen-specific Treg cells [47
&
],
subsequently by allergen-specific Breg cells (Br1
cells), and monocytes. In bee venom-allergic
patients, these IL-10-secreting Tr1 cells are substan-
tially increased very early after the start of bee
venom AIT and persist in high-dose exposure to
allergen models, such as nonallergic beekeepers
and cat owners [48–51]. Tr1 cells are also generated
in response to other immunotherapies such as sub-
lingual immunotherapy, immunotherapy against
other allergens such as grass pollen and house dust




suppressive properties of Treg cells are also regulated
by IL-10 producing Tr1 cells and CD4þCD25þ Treg
cells [55]. Moreover, IL-10 together with TGF-b
revealed the inhibitory functions through the other
subset of Treg cells, inducible T cell co-stimulator
(ICOS)þ forkhead box P3þ Treg cells [56]. IL-10
suppresses T cells via CD28 and ICOS-dependent
T-cell costimulation by precisely blocking prolifera-
tion and cytokines production [57]. In a mice
model, the transfer of ovalbumin peptide-specific
CD4þ CD25þ T cells to OVA-sensitized mice was
determined to be IL-10 dependent. Kearley et al.
[58] demonstrated that the transfer of CD4þ
CD25þ T cells leads to an increased expression of
IL-10 in the lungs and to a decrease in airway
hyperreactivity and the recruitment of eosinophils
and Th2 cytokines to airways after an allergen chal-
lenge. These effects were reversed by administration
of an anti-IL-10R antibody [58]. SLIT with systemic
administration of IL-2 associated with an anti-IL-2
monoclonal antibody (IL-2/anti-IL-2Ab complex or
IL-2C) rendered Treg-mediated tolerance and
reversed the IgE-mediated food allergy in mice [59].
Three different IL-10þ Breg subsets have
been identified in humans. CD19þCD5þCD1dþ
and CD19þCD24þCD38þ Bregs were shown
to suppress Th1 cells [60,61], whereas
CD19þCD25þCD71þCD73-inducible Breg cells
may play a role in allergen-specific immune
tolerance [62
&&
]. These inducible Breg cells (or
Br1 cells) are immunosuppressive B cells that
regulate excessive inflammation via the release
of IL-10, which induce differentiation of regula-
tory T cells and inhibit proinflammatory










Our group investigated the role of B cells in AIT,
by comparing B-cell responses in allergic patients
before and during AIT and naturally exposed
healthy beekeepers before and during the
beekeeping season. Br1 cells are characterized by
high expression of CD25 and CD71 and low
expression of CD73 on the cell surface. We demon-
strated that phospholipase A2 (PLA)-specific B cells
showed similar responses in allergic patients and
beekeepers after venom exposure. Both groups
showed increased frequencies of plasmablasts,
PLA-specific memory B cells, and IL-10-secreting
CD73CD25þCD71þ Br1 cells. Additionally, PLA-
specific IgG4-switched memory B cells expanded
after bee venom exposure [67]. The changes in the
immune response induced upon venom immuno-
therapy have shown that 3–4 months after the start
of the treatment, the frequency of PLA-specific IL-
10-producing Br1 cells increased two-fold to five-
fold, reaching a level comparable to that of healthy
beekeepers during the season [68–70]. Interestingly,
PLA-specific B cells showed increased CCR5 expres-
sion after high-dose allergen exposure, whereas
CXCR4, CXCR5, CCR6, and CCR7 expression
remained unaffected [71
&&
]. The prominent immu-
noregulatory profile of IL10-producing Breg cells
characterized by upregulation of CD25 (IL-2 recep-
tor a chain), programmed death-ligand 1, suppressor
of cytokine signaling 3 (SOCS3), and glycoprotein A
repetitions predominant has been demonstrated by
Stanic et al. [72
&&
]. On a long-term follow-up of
allergen-specific B cells during AIT in house dust
mite allergy, we were able to show that IgG4þ and
immunglobulin A (IgA)þ Der p 1-specific B cells
B-cell responses in allergen immunotherapy Satitsuksanoa et al.
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showed a significant increase after AIT. Responders
showed a significantly greater frequency compared
with nonresponders in the IgG4 but not the IgA
fraction. The frequency of plasmablasts and IL-10þ
and/or IL-1RAþ producing Breg cells was greater
among responders compared with nonresponders
after 2 years. The increased frequency of Der p 1-
specific IgG4þ B cells, plasmablasts, and IL-10þ and
dual-positive IL-10þIL-1RAþ Breg cells significantly
correlated with improved clinical symptoms over
the course of AIT. Therefore, allergen-specific B cells
in patients responding to AIT are characterized by
increased numbers of IgAþ and IgG4þexpressing Der
p 1-specific B cells, plasmablasts, and IL-10þ and/or
IL-1RAþ Breg cells [73
&&
]. In asthmatic mice, the
adoptive transfer of CD9(þ) B cells normalized air-
way inflammation and lung function by inhibiting
Th2 and Th17-driven inflammation in an IL-10-
dependent manner, restoring a favorable immuno-
logical balance in lung tissues. They further showed
that injection of CD9þ Breg cells controls the expan-
sion of lung effector T cells allowing the establish-
ment of a favorable regulatory T cells/effector T cells
ratio in lungs [74]. Several surface markers on Breg
cells are comprehensively described in a recent
review article [64
&&
]. Here, we provide a list of surface
markers on different B-cell subsets in both human
and mouse in Table 1.
Additionally, allergen-specific IgE which is pro-
duced by B cells indisputably plays a key role in
determining the allergen specificity of allergic
disease [75]. Characterization of B-cell receptor
repertoires in different tissues and the evolution
of IgE repertoires in allergen-specific B cells has
become an interesting topic to enhance the under-
standing of allergic responses [76]. A recent study
demonstrated that Ara h 2-specific circulatingmem-
ory B cells are induced early and transiently in
patients undergoing peanut oral immunotherapy
and can be identified by using a fluorescent
multimer. Immunoglobulins from these circulating
Ara h 2-specific B cells are affinity matured and
some clonal groups are shared among unrelated
patients with peanut allergy [77]. Hoh et al. [78]
showed peanut allergen-specific B cells in patients
express mutated antibody genes, usually of switched
isotypes and bind to both linear and conformational
epitopes. Even well-defined linear epitopes of aller-
gen proteins can be recognized bymultiple indepen-
dent B-cell clones in a single patient. Increased
frequencies of allergen-binding B cells, progressive
somatic mutation of IgG4, but not IgE, are observed
during AIT [78]. Therefore, IgE repertoire persistence
and evolution could be considered as markers for
monitoringAIT inpatientswith allergic diseases [79].
Together these studies provide a first detailed
characterization of allergen-specific B cells before
and after immune tolerance induction in bee
venom, house dust mite, and peanut allergies as
shown in Table 2. It is clear that the responses of
B cells in AIT are very essential; however, to get a full
understanding of all mechanisms, they need to be
further investigated in-depth.
CONCLUSION
AIT has been considered as the most powerful treat-
ment in patients who suffer from allergy, cancer,
and autoimmune diseases [13,80]. Immune toler-
ance development was aimed for allergy and auto-
immunity treatment, whereas enhancement of
immune effector functions was aimed in cancer
therapy. The development of immune tolerance
requires allergen-specific Breg and Treg cells,
increased IgG4 isotype-specific antibody response,
and decreased activation of effector cells, such as
basophils, mast cells, and eosinophils. Breg cells are
interesting targets for the improvement of new
therapies in the induction of immune tolerance.
Advances in mechanisms of AIT has been aiming
Table 1. The list of surface markers on Breg cells and Br1 cells
Types Human Mouse Function




Suppress Th2 cells, and Th2 cytokines
Br1 cells [67,84] CD19þCD73CD25þCD71þ CD19þCD5þ Suppress IgE production, upregulate
of IgG4 production in human, and
increase IL-10 production both
in human and mouse
Immature B cells [61,85–87] CD19þCD24hiCD38hi CD19þCD21hiCD23hi
CD24hiIgMhiIgDhiCD1dhi
Transitional B cells based on the
phenotypes and ontogeny
Plasmablasts [88] CD27intCD38hi CD138þCD44hi A short-lived and proliferating
antibody-secreting cells
Breg, regulatory B cells; Br1, allergen-specific Breg cells; Th2, T-helper 2 cells.
Immunotherapy and new treatments
636 www.co-allergy.com Volume 19  Number 6  December 2019
 Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
to ensure that more efficient AIT vaccines are devel-
oped with low side-effects and higher efficacy and
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